Gaucher disease: haematological presentations and complications.
about
Profile of eliglustat tartrate in the management of Gaucher diseaseRole of Ceramide from Glycosphingolipids and Its Metabolites in Immunological and Inflammatory Responses in HumansHematological manifestations and complications of Gaucher disease.Treatment of profound thrombocytopenia in a patient with Gaucher disease type 1: Is there a role for substrate reduction therapy.Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease.Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapyImprovement in Bone Mineral Density and Architecture in a Patient with Gaucher Disease Using Teriparatide.Gaucher Disease-Induced Pluripotent Stem Cells Display Decreased Erythroid Potential and Aberrant Myelopoiesis.Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease.The prognostic value of the serum ferritin in a southern Brazilian cohort of patients with Gaucher diseaseNine-year experience in Gaucher disease diagnosis at the Spanish reference center Fundación Jiménez DíazEvaluation of bone involvement in patients with Gaucher disease: a semi-quantitative magnetic resonance imaging method (using ROI estimation of bone lesion) as an alternative method to semi-quantitative methods used so far.Clinical Utility of Bone Marrow Study in Gaucher Disease: A Case Report of Gaucher Disease Type 3 With Intractable Myoclonic Seizures.Altered Differentiation Potential of Gaucher's Disease iPSC Neuronal Progenitors due to Wnt/β-Catenin Downregulation.Patients' Opinions on Genetic Counseling on the Increased Risk of Parkinson Disease among Gaucher Disease Carriers.Diastereomer-specific quantification of bioactive hexosylceramides from bacteria and mammals.Non-neoplastic histiocytic and dendritic cell disorders in lymph nodes.Tuning protein folding in lysosomal storage diseases: the chemistry behind pharmacological chaperones.A health state utility valuation study to assess the impact of treatment mode of administration in Gaucher disease
P2860
Q26774416-D422137A-68E0-4A06-8968-0CB6736E79FCQ28080555-8B81C447-A4A4-494A-AE74-24BCE0A84B99Q33427535-9F123654-878D-4E51-86CD-8F5404D8E12BQ33443605-1FE47FA0-8450-4B16-BDAD-618B6900DA51Q33634529-E63A46DC-8D99-410D-A1A9-E93A949AE9A4Q33692023-A0F75F51-A354-4052-86D6-A55C82BE7AA4Q35801017-8C8C4EC1-CA0B-4D4C-A763-6DF937949746Q35878866-6CC9A96B-0251-4C2A-8E1F-FB7597DB450AQ36220187-8AAB0EA0-199A-46D0-A7C0-ADFFC4167E4CQ36727748-17DBBEEB-C583-4770-B233-BBC20EB786D7Q37414072-82113F0A-15A2-4DF8-8B54-CB18383DED21Q41489523-12B5B6EC-7E90-40CE-8DB3-70228DD30E04Q43087363-447A3D58-5597-461A-85CA-60D712C3AB7FQ47289706-C936F849-2D13-45BD-B9A6-6129C057A5C8Q48266068-339EA3B6-4CFB-4137-8B8B-77CF6887372BQ48326911-9F5D704F-207F-4C22-850F-E91A8A82DD95Q49914611-5B868170-DC17-4EAF-8788-20DDD3C43A86Q54945677-1944A2CB-9961-4FAB-B65B-915723A895A2Q57159147-07E22021-224F-4C2C-8C17-98D7EB71ACC0
P2860
Gaucher disease: haematological presentations and complications.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Gaucher disease: haematological presentations and complications.
@ast
Gaucher disease: haematological presentations and complications.
@en
type
label
Gaucher disease: haematological presentations and complications.
@ast
Gaucher disease: haematological presentations and complications.
@en
prefLabel
Gaucher disease: haematological presentations and complications.
@ast
Gaucher disease: haematological presentations and complications.
@en
P356
P1476
Gaucher disease: haematological presentations and complications.
@en
P2093
Alison S Thomas
Atul Mehta
P304
P356
10.1111/BJH.12804
P407
P577
2014-03-03T00:00:00Z